Phase 2 Startnegative

Phase 2 Start: An Attenuated Schedule Dara-RVd Induction for Patients With Newly Diagnosed Multiple Myeloma Who Are

Indication
Multiple Myeloma; Newly Diagnosed Multiple Myeloma; Autologous Stem Cell Transplantation

Other upcoming events for FATE

Phase 2 StartPhase 2 Start: A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Refractory Moderate-to-Severe
Phase 2 StartPhase 2 Start: Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor
Phase 3 ReadoutPhase 3 Topline: Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or
Phase 3 ReadoutPhase 3 Topline: A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bev
Phase 3 ReadoutPhase 3 Topline: Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic H

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 2 Start: An Attenuated Schedule Dara-RVd Induction for Patients With Newly Diagnosed Multiple Myeloma Who Are — FATE Phase 2 Start | BioSniper